Antiva Biosciences
Del Mar
About Antiva Biosciences
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. They aim to prevent cancer by treating precancerous lesions caused by HPV. Their programs are in clinical trials for high-grade anal intraepithelial neoplasias (AIN 2,3) and high-grade cervical intraepithelial neoplasias (CIN 2,3).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $141.0M
- Funding stage: Late Stage Venture
- Last round: Series E (Apr 2023)
- Website: antivabio.com
- Phone: (650)822-1400
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/antiva-biosciences-67510 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.